PATH Resources

Our online catalog indexes publications, presentations, and related resources for peers in our field.

2150 Resources
2150 Resources
2150 Resources
    Date
    From
    To
  1. This slide provides a snapshot of the respiratory syncytial virus (RSV) vaccine and monoclonal antibody (mAb) technology landscape, in the effort to track the development of RSV vaccine and mAb candidates and provide a summary of the various vaccine approaches being worked on worldwide. (This snapshot pairs with the RSV and mAb Trial Tracker, which provides publicly available information on clinical trials of RSV candidate vaccines and mAbs intended for prevention.)
    Published: January 2023
    Resource Page
    Part of a Series, Infographic, Training Material, Brief
  2. Stakeholder-Led Advancement of Mental Health of Young People (SAMYP) is a landmark project that has synthesized the national landscape of the youth mental health ecosystem in India. To address the mental health needs of young people aged 15-24 years, PATH, with support from Fondation Botnar, analyzed multisectoral policies and programs, held stakeholder consultations, and convened the Technical Advisory Group and Youth Advisory Group comprised of young people with lived experience of mental health conditions.SAMYP has highlighted that India’s existing programmatic landscape is yet to realize its full potential to advance youth mental health. It has also emphasized the need for innovative ways to address fundamental challenges related to providing sustainable access to accurate mental health information, resources, and basic mental health care. PATH has developed and disseminated high quality, reliable, and ready-reference knowledge products, such as the landscape report, technical briefs, white paper series, and stories to promote mental health literacy and make it a national priority.
    Published: January 2023
    Resource Page
    Part of a Series, Brief, Report
  3. Virus hunter: Environmental surveillance and the polio endgame
    Published: January 2023
    Resource Page
    Fact Sheet
  4. Human papillomavirus (HPV) vaccine programs in low- and middle-income countries face financial, programmatic, and social barriers to the introduction and sustainability of these programs. An HPV vaccine delivered through a microarray patch (MAP) could offer potential advantages to address some of those barriers. We asked global experts and stakeholders in Ethiopia about the acceptability and programmatic suitability of this option. In this report, we share the input from these stakeholders, both in terms of programmatic advantages and concerns regarding an HPV vaccine MAP, as well as some of their desired attributes.
    Published: December 2022
    Resource Page
    Report
  5. Shigella is the leading bacterial cause of childhood diarrhea, and infections can have long-term effects on growth and development. No licensed Shigella vaccines currently exist, but several promising candidates in development could become available in a few years. PATH conducted a series of studies to better understand the public health value of potential Shigella vaccines and help inform decisions by international agencies, funders, vaccine developers, and national policymakers. This included: vaccine impact and cost-effectiveness analyses, demand forecasts for two potential markets, an expert consultation on Shigella-containing combination vaccines, and a feasibility and acceptability study with national stakeholders and healthcare providers in five countries. This brief provides a comprehensive summary of the results.
    Published: December 2022
    Resource Page
    Brief